185 related articles for article (PubMed ID: 27291833)
1. Adherence predicts symptomatic and psychosocial remission in schizophrenia: Naturalistic study of patient integration in the community.
Bernardo M; Cañas F; Herrera B; García Dorado M
Rev Psiquiatr Salud Ment; 2017; 10(3):149-159. PubMed ID: 27291833
[TBL] [Abstract][Full Text] [Related]
2. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.
Bressington D; Mui J; Gray R
Int J Ment Health Nurs; 2013 Feb; 22(1):35-46. PubMed ID: 22738372
[TBL] [Abstract][Full Text] [Related]
4. The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia.
Valencia M; Fresan A; Juárez F; Escamilla R; Saracco R
J Psychiatr Res; 2013 Dec; 47(12):1886-92. PubMed ID: 24112947
[TBL] [Abstract][Full Text] [Related]
5. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
[TBL] [Abstract][Full Text] [Related]
6. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
[TBL] [Abstract][Full Text] [Related]
7. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
8. [Predictors of medication non-adherence among a Moroccan sample of patients with schizophrenia: A cross sectional study].
El Ammouri A; Kisra H
Encephale; 2017 Dec; 43(6):522-527. PubMed ID: 27663045
[TBL] [Abstract][Full Text] [Related]
9. Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment.
Barak Y; Aizenberg D
BMC Psychiatry; 2012 Aug; 12():108. PubMed ID: 22882755
[TBL] [Abstract][Full Text] [Related]
10. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
[TBL] [Abstract][Full Text] [Related]
11. Control beliefs, therapeutic relationship, and adherence in schizophrenia outpatients: a cross-sectional study.
Jaeger S; Weißhaupt S; Flammer E; Steinert T
Am J Health Behav; 2014 Nov; 38(6):914-23. PubMed ID: 25207516
[TBL] [Abstract][Full Text] [Related]
12. Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia.
El-Missiry A; Elbatrawy A; El Missiry M; Moneim DA; Ali R; Essawy H
J Psychiatr Res; 2015 Nov; 70():106-12. PubMed ID: 26424429
[TBL] [Abstract][Full Text] [Related]
13. Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.
Vassileva I; Milanova V; Asan T
Community Ment Health J; 2014 Oct; 50(7):854-61. PubMed ID: 24452824
[TBL] [Abstract][Full Text] [Related]
14. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.
Novick D; Haro JM; Suarez D; Vieta E; Naber D
Schizophr Res; 2009 Mar; 108(1-3):223-30. PubMed ID: 19070991
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study.
Novick D; Haro JM; Suarez D; Lambert M; Lépine JP; Naber D
Psychopharmacology (Berl); 2007 May; 191(4):1015-22. PubMed ID: 17310386
[TBL] [Abstract][Full Text] [Related]
16. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
[TBL] [Abstract][Full Text] [Related]
17. Novelty seeking and medication adherence in patients with schizophrenia.
Aukst Margetić B; Jakovljević M; Ivanec D; Tošić G; Margetić B
Psychiatry Res; 2011 Mar; 186(1):141-3. PubMed ID: 20630601
[TBL] [Abstract][Full Text] [Related]
18. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
19. Adherence to Antipsychotic Medication by Community-Based Patients With Schizophrenia in China: A Cross-Sectional Study.
Wang X; Zhang W; Ma N; Guan L; Law SF; Yu X; Ma H
Psychiatr Serv; 2016 Apr; 67(4):431-7. PubMed ID: 26725294
[TBL] [Abstract][Full Text] [Related]
20. Relationships among medication adherence, insight, and neurocognition in chronic schizophrenia.
Na E; Yim SJ; Lee JN; Kim JM; Hong K; Hong MH; Han H
Psychiatry Clin Neurosci; 2015 May; 69(5):298-304. PubMed ID: 25600955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
